Gilead Sciences, Inc.
Explore Gilead Sciences
Core profile pages, annual revenue records, and related research hubs for this company.
Gilead Sciences, Inc.
Explore Gilead Sciences
Core profile pages, annual revenue records, and related research hubs for this company.
Business Model Analysis
Annual Revenue: $29.4B
Gilead makes money by discovering, developing, manufacturing, and commercializing patented medicines, with FY2025 revenue led by HIV therapies and supported by liver-disease, oncology, cell-therapy, and royalty/contract revenue. The HIV franchise generated $20.8 billion in product sales in 2025, led by Biktarvy at $14.3 billion, while Veklury continued to decline as COVID-19 hospitalizations normalized. The model depends on patent-protected pricing, clinical evidence, global market access, manufacturing reliability, and pipeline renewal through internal R&D and acquisitions.
Gilead's growth strategy centers on extending its HIV leadership with long-acting lenacapavir, defending Biktarvy through lifecycle evidence, expanding liver-disease medicines, and scaling oncology through Trodelvy and Kite cell therapies. CEO Daniel P. O'Day is balancing R&D investment, business development, manufacturing capacity, and shareholder returns as the company prepares for future HIV patent expirations and continued pricing scrutiny. The FY2025 results give Gilead a larger earnings base than the prior file suggested, but the strategic question remains whether next-generation HIV prevention and oncology can offset eventual pressure on legacy antivirals.
Gilead makes money from patent-protected medicines, specialty drug sales, licensing, collaborations, and acquired therapies.
Gilead sells HIV treatments, antiviral drugs, oncology medicines, cell therapies, and specialty pharmaceuticals to patients, physicians, hospitals, payers, pharmacies, and public-health systems.
Gilead serves patients, physicians, hospitals, payers, pharmacies, and public-health systems, with demand shaped by its industry, channels, and product portfolio.
The model shows how Gilead converts products, customer relationships, and scale into recurring revenue and profit potential.